Search results
Results from the WOW.Com Content Network
Tenofovir also interacts with HIV-1 protease inhibitors such as atazanavir, by decreasing atazanavir concentrations while increasing tenofovir concentrations. [10] In addition, since tenofovir is excreted by the kidney, medications that impair renal function can also cause problems. [16]
Non-nucleoside reverse transcriptase inhibitor: Tenofovir disoproxil: ... New or worsening kidney problems, including kidney failure; Onset of depressive disorders or ...
At the time of Complera's approval, there were concerns about the US$20,500 wholesale cost of efavirenz/emtricitabine/tenofovir (Atripla), which is marketed by Gilead and Bristol-Myers Squibb. HIV drug prices have increased substantially.
Patients are advised to discuss any history of bone issues, kidney issues, or hepatitis B infection with their healthcare provider. [19] Effectiveness of PrEP for prevention of infection is reliant on an individual's ability to take the medication consistently. [20] Emtricitabine/tenofovir is also used for HIV post-exposure prophylaxis. People ...
For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients with kidney failure than they are in patients with normal kidney function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors and explain sources of variability that ...
It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease [8] and is given in combination with other medications for the prevention and treatment of HIV. It is taken by mouth. [6] Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor and is a prodrug of tenofovir.
Underlying hepatitis B virus (HBV) can interact with emtricitabine to cause significant liver damage, but it does not have a significant detrimental effect on the liver when given to patients without HBV. [18] Tenofovir alafenamide (TAF) is a prodrug of tenofovir that functions as a nucleotide reverse transcriptase inhibitor (NtRTI). Other ...
It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. [2] It is taken by mouth. [3] Side effects may include trouble sleeping, weight gain, and rash.